RAPID-C19 is a multi-agency initiative. It aims to get treatments for COVID-19 to NHS patients quickly and safely.
It also helps frontline staff in health and social care understand the options they have for treating affected patients.
The initiative is a collaboration between:
- NHS England and NHS Improvement
- the Medicines and Healthcare products Regulatory Agency (MHRA)
- the National Institute for Health Research (NIHR)
- Scottish Medicines Consortium (Healthcare Improvement Scotland)
- All Wales Therapeutics and Toxicology Centre
- All Wales Medicines Strategy Group
- Northern Ireland Health and Social Care Board.
How it works
There are lots of clinical trials underway, working to find effective COVID-19 treatments.
RAPID-C19 works to speed up access to treatments where the research shows there is clinical benefit and they're proven to be safe and effective.
Primary horizon scanning and initial stratification
The NIHR Innovation Observatory scans all national and international trials for COVID-19 treatments. This includes:
- all anti-virals, both anti-inflammatory and immunomodulatory
- all cell-based therapies
- other pharmacological treatments.
Briefing and rapid action plan development
NICE gathers information from collaborating organisations, companies and other sources. This may involve liaising with trial sites or company representatives.
This information helps development of briefing notes and rapid action plans for the RAPID C-19 oversight group.
RAPID-C19 oversight group review
The collaborating organisations consider and discuss the briefing notes to identify treatments to be accelerated. Actions required could relate to:
- potential licensing approaches
- producing evidence summaries
- developing commissioning policies
- other activities needed to prepare the system to receive and deliver these treatments.
Rapid regulatory signal and process
The MHRA considers how to accelerate the regulatory access to the identified treatments. This includes licence extensions and revisions as well as approaches for previously unlicensed drugs.
Application of regulatory signal to patient access
NHS England and NHS Improvement makes sure the selected treatments can be delivered. This could include developing a commissioning policy or initiating an evidence review.
Health technology assessment or licensing
NICE starts the HTA process and the MHRA completes any remaining licensing arrangements for each of the selected treatments.
The initiative has already given NHS patients rapid access to 2 treatments: